NoneNo Change
Bleeding events
Aspirin → Bleeding events
Aspirin → Bleeding events
Evidence profile
NoneNo ChangeSafety
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Ticagrelor monotherapy reduces bleeding in diabetic ACS patients
Key finding
There was no significant difference in the incidence of MACE between the two groups during 12 months of follow-up.
This study evaluated ticagrelor monotherapy after 3 months of dual antiplatelet therapy in diabetic patients with acute coronary syndrome, finding no significant difference in major adverse cardiovascular events.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Some Concerns bias
Last updated July 6, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Ticagrelor monotherapy after 3 months of DAPT, Ticagrelor plus aspirin for 12 months
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Primary outcome
Major adverse MACE
Comparator
Dual Antiplatelet Therapy Group
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated ticagrelor monotherapy after 3 months of dual antiplatelet therapy in diabetic patients with acute coronary syndrome, finding no significant difference in major adverse cardiovascular events.
Clinical relevance
These findings are significant for clinicians managing diabetic patients with acute coronary syndrome, as they suggest that switching to ticagrelor monotherapy may reduce bleeding risks without compromising cardiovascular safety. This could lead to more tailored treatment strategies that balance efficacy and safety.
Keep in mind
The study's sample size and population may limit generalizability. The follow-up period was only 12 months, which may not capture long-term outcomes. Effect sizes were unclear, limiting the strength of conclusions.
Published in
Journal Reference
Publication details and source links for this paper.
Nour EMSI, Mohamed TMZ, Khaled AFAM, Khaled AF, Mina MAI. Ticagrelor Monotherapy After 3 Months of Dual Antiplatelet Treatment in Diabetic Patients with Acute Coronary Syndrome. BMC Cardiovascular Disorders. 2026;26:300. doi:10.1186/s12872-026-05708-w
Save this study and add notes to your research library.
Main Effects
No significant difference in major adverse cardiovascular events between ticagrelor monotherapy and dual therapy (p-value: null).
Ticagrelor monotherapy was associated with a decrease in overall bleeding events, particularly mild bleeding.
Rates of moderate or severe bleeding were comparable between both treatment groups.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Aspirin, Ticagrelor monotherapy after 3 months of DAPT and Bleeding events, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).
This study contributes evidence to
Primary intervention
Aspirin
Primary outcomes
- Bleeding events
- Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 63
1
Related topics
4
Evidence pairs
33
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
NoneNo Change
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Aspirin → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Aspirin → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence profile
NoneNo ChangeClinical Outcomes
Unlock full evidence details
StrongDecrease
Bleeding events
Ticagrelor monotherapy after 3 months of DAPT → Bleeding events
Ticagrelor monotherapy after 3 months of DAPT → Bleeding events
Evidence profile
StrongDecreaseSafety
Unlock full evidence details
NoneNo Change
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Ticagrelor monotherapy after 3 months of DAPT → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Ticagrelor monotherapy after 3 months of DAPT → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence profile
NoneNo ChangeClinical Outcomes
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- No change in major adverse cardiovascular events with ticagrelor monotherapy.
- Ticagrelor monotherapy showed a decrease in overall bleeding events.
- Moderate or severe bleeding rates were similar in both treatment groups.
Who this applies to
- Diabetic patients diagnosed with acute coronary syndrome.
- Patients who have completed at least three months of dual antiplatelet therapy.
Keep in Mind
- Results may not apply to non-diabetic patients or those with different coronary conditions.
- The study did not assess long-term outcomes beyond 12 months.
- Further research is needed to confirm findings in larger, diverse populations.
Between the Lines
- The study's sample size and population may limit generalizability.
- The follow-up period was only 12 months, which may not capture long-term outcomes.
- Effect sizes were unclear, limiting the strength of conclusions.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Ticagrelor monotherapy after 3 months of DAPT and Bleeding events.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Bleeding events Evidence Hub
All studies measuring Bleeding events
1 studies
outcome_hubMeasures Bleeding events as a key outcome.
Ticagrelor monotherapy after 3 months of DAPT Evidence Hub
All studies on Ticagrelor monotherapy after 3 months of DAPT
1 studies
intervention_hubContributes to Ticagrelor monotherapy after 3 months of DAPT evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Ticagrelor monotherapy after 3 months of DAPT and Bleeding events
Intervention: Ticagrelor monotherapy after 3 months of DAPTOutcome: Bleeding events
1 results
All studies on Ticagrelor monotherapy after 3 months of DAPT
Intervention: Ticagrelor monotherapy after 3 months of DAPT
1 results
All studies measuring Bleeding events
Outcome: Bleeding events
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Ticagrelor monotherapy after 3 months of DAPT improve bleeding events?
Emerging Evidence
Ticagrelor monotherapy after 3 months of DAPT appears to improve Bleeding events.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Bleeding events
EvidenceScore™ Emerging | EvidenceScore™ 54.2 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Aspirin improve bleeding events?
Limited Evidence
Current evidence does not show a clear benefit of Aspirin for Bleeding events.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Bleeding events
EvidenceScore™ Limited | EvidenceScore™ 36.6 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Aspirin improve composite cardiovascular events (cv death, mi, stroke, hf hospitalization)?
Limited Evidence
Current evidence does not show a clear benefit of Aspirin for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Limited | EvidenceScore™ 36.6 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Ticagrelor monotherapy after 3 months of DAPT improve composite cardiovascular events (cv death, mi, stroke, hf hospitalization)?
Limited Evidence
Current evidence does not show a clear benefit of Ticagrelor monotherapy after 3 months of DAPT for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Limited | EvidenceScore™ 36.6 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Explore in archive
Open broader archive views for this relationship.
All studies on Aspirin and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)All studies on Ticagrelor monotherapy after 3 months of DAPT and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)All studies on Ticagrelor monotherapy after 3 months of DAPT and Bleeding eventsAll studies on Aspirin and Bleeding events
Related research
Read related research summaries.
HbA1c mediates cardiovascular benefits of GLP-1 receptor agonistsIntensive glycemic control may lower cardiovascular events in some diabetes patientsLinking Eye Screening Data Improves Understanding of Diabetes TreatmentsTighter glycaemic targets may reduce serious infant morbidityWomen and frailty linked to poorer adherence in diabetes trial
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.